Clearing the way
We explore the technology behind AviClear®, the first and original FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne.
As acne affects 742 million patients daily, an alarming 48% are unsatisfied with their current acne treatment.1,2 But the acne treatment landscape is changing with the introduction of AviClear® by Cutera®, the first and original FDA cleared device for long-term treatment of mild, moderate, and severe inflammatory acne.
AviClear® utilises a 1726nm wavelength laser designed to target sebaceous glands and reduce sebum production. This treatment is both effective and safe for all skin tones and Fitzpatrick skin types, requiring three 30-minute sessions spaced approximately one month apart. It successfully addresses all severities and forms of acne, including hormonal, cystic, and inflammatory types. By tackling acne at its root cause, AviClear® provides patients with long-lasting results and clearer skin, eliminating the reliance on inconvenient prescription medications and complex home care routines.
As dermatologists and practitioners know, traditional acne treatment protocols can be bothersome and frustrating for many patients. Antibiotics may work, but acne often returns once they are no longer taken. Retinoids and other topical prescription medications may effectively treat acne but rely on patient compliance. Isotretinoin is often used when all other treatments have failed, but common side effects like dry skin, rash, irritation, and an increase in the risk of birth defects often lead to patient resistance. AviClear® was created to help patients avoid these issues by providing a new solution for acne, which hasn’t been done in decades.
Clinical trials have yielded positive results, with most patients experiencing fewer, shorter, and less intense acne breakouts following AviClear® treatment.4 As demonstrated in the chart, the trial results are equally impressive: 80% of patients reported that half of their acne resolved three months after their final treatment, 87% noted the same improvement six months after their final treatment, and 92% saw at least half of their acne resolved 12 months post-treatment. Moreover, long-term data revealed continued improvement up to 24 months after the final treatment, with a 97% reduction in inflammatory lesion count (ILC).5 This pattern of improvement is clear; unlike conventional acne treatments, AviClear® enables patients to achieve ongoing results long after their treatment, without side effects or the need for prescriptions.
Patients observe visible improvements shortly after their final treatment session, with most experiencing continued progress for months afterwards. Alongside these results, AviClear®’s AviCool™ sapphire contact skin cooling and sensory controls provide a comfortable treatment experience. This exceptional combination positions AviClear® as a groundbreaking and highly effective acne treatment for modern times.
AviClear® is rapidly emerging as the new gold standard for acne treatment, with dermatologists noting that its results are comparable to those of isotretinoin but without the associated drawbacks. There is no downtime, no blood tests, and no prescriptions required. Patients are validating these outcomes, with over nine out of ten self-reporting being either satisfied or very satisfied.3
AviClear has revolutionised acne treatments, as forward-thinking dermatologists and practitioners recognise that the solution is clear. AviClear is fast becoming a top choice for acne treatment among providers and patients alike. By effectively addressing mild to severe acne while meeting patient demands for treatments that are convenient, easy, and safe, providers are truly bringing the future of acne care directly into their practices.
For more information on AviClear please visit: https://aviclear.com/en-uk/